Activation of the PI3K/Akt pathway and chemotherapeutic resistance-Reference-Cited by-同舟云学术

Activation of the PI3K/Akt pathway and chemotherapeutic resistance

Published:2002-12 Issue:6 Volume:5 Page:234-248
ISSN:1368-7646
Container-title:Drug Resistance Updates
language:en
Short-container-title:Drug Resistance Updates

Author:

West Kip A,Sianna Castillo S,Dennis Phillip A

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Cancer Research,Pharmacology,Oncology

Reference148 articles.

1. Delayed mammary gland involution in MMTV-AKT1 transgenic mice;Ackler;Oncogene,2002

2. FKBP-rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early G1 of an osteosarcoma cell line;Albers;J. Biol. Chem.,1993

3. Immunohistochemical localization of phosphorylated AKT in multiple myeloma;Alkan;Blood,2002

4. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression;Anderson;Int. J. Cancer,2001

5. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells;Asselin;Cancer Res.,2001

Cited by 521 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling effect, combinations, and clinical applications of triciribine;Journal of Chemotherapy;2024-09-14

2. Newly developed humanized anti‐CKAP4 antibody suppresses pancreatic cancer growth by inhibiting DKK1‐CKAP4 signaling;Cancer Science;2024-08-08

3. The story of clobenpropit and CXCR4: can be an effective drug in cancer and autoimmune diseases?;Frontiers in Pharmacology;2024-07-12

4. Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models;Cancer Research Communications;2024-06-05

5. The role of miRNAs as biomarkers in breast cancer;Frontiers in Oncology;2024-05-15